| abstract |
Pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution improving agent sufficient to substantially dissolve the antineoplastic agent in at least one aqueous diluent, where the dissolution improving agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising the pharmaceutical formulation, and articles of manufacture thereof. Claim 2: The pharmaceutical formulation according to claim 1, wherein the antineoplastic agent is temozolomide, mustard uracil, chlormethine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine, triethylene thiophosphoramide, busulfan, carmustine, lomustine, streptozocin, dacarbazine, methotrexate, 5-fluoruracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, phytabine, vintinine, vintinine dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, paclitaxel, mitramycin, deoxicoformicin, mitomycin-C, L-asparaginase, interferons, etoposide, teniposide, 17.a-ethinyl estradiol, diethylstilbestrol, testosterone, testosterone, testosterone, testosterone megestrolacetate, tamoxifen, methylprednisolone, methyltestostero na, prednisolone, triamcinolone, chlorotrianisene, hydroxyprogesterone, aminoglutethimide, estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, carboplatin, hydroxyurea, amsacrine, procarbazine, mitotane, mitoxantrone, levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, droloxaphine, hexamethylmelamine, and mixtures thereof. Claim 3: The pharmaceutical formulation according to claim 2, wherein the antineoplastic agent is temozolomide. |